[
    [
        {
            "time": "2020-12-15",
            "original_text": "医药生物行业跨市场周报：2020年医保谈判结束 BIO TECH和创新药路在何方？",
            "features": {
                "keywords": [
                    "医保谈判",
                    "BIO TECH",
                    "创新药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：2020年医保谈判结束 BIO TECH和创新药路在何方？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-12-20",
            "original_text": "2020险资投资图谱：头部机构成举牌主力 科技、消费股备受调研青睐",
            "features": {
                "keywords": [
                    "险资",
                    "科技",
                    "消费股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2020险资投资图谱：头部机构成举牌主力 科技、消费股备受调研青睐",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-01-05",
            "original_text": "医疗板块2021年度策略：把握三大主线",
            "features": {
                "keywords": [
                    "医疗板块",
                    "年度策略",
                    "三大主线"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "医疗板块2021年度策略：把握三大主线",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-01-10",
            "original_text": "中国疫苗获突破性进展！聪明资金扫货4000亿白马",
            "features": {
                "keywords": [
                    "疫苗",
                    "突破性进展",
                    "聪明资金"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国疫苗获突破性进展！聪明资金扫货4000亿白马",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-15",
            "original_text": "高瓴、高盛、大摩、红杉资本最新调研透露2021年布局方向，科技股和医药股仍是座上宾",
            "features": {
                "keywords": [
                    "高瓴",
                    "高盛",
                    "科技股",
                    "医药股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴、高盛、大摩、红杉资本最新调研透露2021年布局方向，科技股和医药股仍是座上宾",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-20",
            "original_text": "粤开医药行业深度：免疫诊断技术迭代 化学发光引领变革浪潮",
            "features": {
                "keywords": [
                    "免疫诊断",
                    "化学发光",
                    "技术迭代"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "粤开医药行业深度：免疫诊断技术迭代 化学发光引领变革浪潮",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-01-25",
            "original_text": "医药生物行业报告：医保谈判落地不确定性消除 加大医药优质赛道关注度",
            "features": {
                "keywords": [
                    "医保谈判",
                    "不确定性消除",
                    "优质赛道"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "医药生物行业报告：医保谈判落地不确定性消除 加大医药优质赛道关注度",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-01",
            "original_text": "医药生物行业周报：“三重行业红利 五重公司催化”助推智飞生物 强调Q1医药躁动机会",
            "features": {
                "keywords": [
                    "行业红利",
                    "公司催化",
                    "智飞生物",
                    "Q1躁动机会"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：“三重行业红利 五重公司催化”助推智飞生物 强调Q1医药躁动机会",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-05",
            "original_text": "医药板块2021年春季行情如何？",
            "features": {
                "keywords": [
                    "医药板块",
                    "春季行情"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药板块2021年春季行情如何？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-10",
            "original_text": "【医药生物*朱国广】医药浪潮之巅后的新选择，估值OR信仰？",
            "features": {
                "keywords": [
                    "医药浪潮",
                    "估值",
                    "信仰"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【医药生物*朱国广】医药浪潮之巅后的新选择，估值OR信仰？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-15",
            "original_text": "医药股年内波动大，基金经理把脉春季行情",
            "features": {
                "keywords": [
                    "医药股",
                    "波动",
                    "春季行情"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药股年内波动大，基金经理把脉春季行情",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]